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gene: a case report
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Abstract
Background: Pure exercise intolerance associated with exclusive affection of skeletal muscle is a very rare phenotype
of patients with mitochondrial myopathy. Moreover, the exercise intolerance in these rare patients is yet not well
explored, as most of known cases have not been assessed by objective testing, but only by interview. We report a
patient with a mitochondrial DNA (mtDNA) mutation that gives rise to an exclusive myopathy associated with exercise
intolerance and ophthalmoplegia. We quantified the patient’s exercise intolerance through detailed exercise testing.
Case presentation: A 39-year-old man presented with exercise intolerance and chronic progressive external
ophthalmoplegia. Sequencing of the entire mtDNA identified a m.12,294G > A mutation in the MT-TL2 gene. The
mutation was heteroplasmic in skeletal muscle (75%) while undetectable in blood, urinary sediment, and buccal
mucosa as well as in tissues from the patient’s mother. The mutation affected a highly conserved site in the anticodon
stem of the mitochondrial transfer RNA Leucine (CUN) molecule and lead to a severe combined respiratory chain defect.
Exercise physiological studies in the patient demonstrated a significantly reduced maximal oxygen uptake of 20.4 ml
O2 × min
−1 × kg−1 (about half of normal) as well as threefold elevated lactate/pyruvate ratios.
Conclusion: The findings of our study support that the m.12,294G > A mutation is pathogenic. Likely, the mutation
arose sporadically in early embryogenesis after differentiation of the mesoderm into muscle progenitor cells, leading to a
pure myopathic phenotype.
Keywords: Case report, Mitochondrial DNA, MT-TL2 mutation, Mitochondrial myopathy, Exercise intolerance, Exercise
physiological study, Maximal oxidative capacity
Background
Point mutations in mitochondrial DNA (mtDNA) trans-
fer RNA (MT-T) genes are associated with a wide variety
of disorders that can affect virtually every tissue in the
body. In the vast majority of cases, multiple tissues are
affected simultaneously causing a multisystemic disease
presentation, usually affecting highly oxidative tissues,
such as the central nervous system and skeletal muscle,
the most [1]. However, rarely a phenotype of isolated
organ involvement is observed. In less than 1% of all
cases of mtDNA point mutations, the phenotype is ex-
clusively present in skeletal muscle, and presents as ex-
ercise intolerance and chronic progressive external
ophthalmoplegia (CPEO) [2]. In most of these rare cases,
the exercise intolerance has not been assessed by object-
ive testing, but only by interview. Exercise intolerance
can be quantified by measuring the maximal oxygen up-
take (VO2max) as well as assessing resting and peak
exercise-induced serum lactate levels and lactate/pyru-
vate ratios (L/P).
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In this case report, we describe a patient with a previ-
ously reported m.12,294G > A mutation in the MT-TL2
gene, who presents with pure exercise intolerance and
CPEO. We performed detailed clinical, laboratory, and
exercise physiological testing to describe the condition




A 39-year-old man presented with a history of exercise
intolerance that could be traced back to the first decade
of his life. For example, during physical education classes
in school he could not keep up with his classmates re-
stricted by shortness of breath, muscle pain, fatigue,
nausea, and even on some occasions vomiting from ex-
haustion. At age 39, he still complained of intolerance to
physical exertion, and complained of persistent fatigue
in his daily life, but was still able to perform all activities
of daily living and work full-time as a maintenance en-
gineer – a job of manually repairing industrial machin-
ery. He had longstanding (> 15 years) bilateral ptosis
that progressed and led to recent eyelid elevation sur-
gery on his right eye. At the time of surgery, he was
found to have external ophthalmoplegia and therefore
referred to our mitochondrial clinic for further investiga-
tion for a possible mitochondrial disorder. He com-
plained of no other symptoms than the fatigue and
exercise intolerance. He had a past medical history of
uncomplicated surgery for both umbilical hernia and bi-
lateral tonsillitis in childhood. Family history was unre-
markable. In particular, his mother, aged 64, was fully
active with no signs of exercise intolerance or ptosis.
On examination, he had moderate, constant, and
asymmetrical ptosis that was most evident on the left
non-operated eye. There was prominent bilateral gaze
palsy to 30° horizontally, 15° upwards, while downwards
gaze was almost normal. He presented with generalized
reduced muscle bulk, but without overt muscle wasting
or weakness and with a height of 179 cm and weight of
73 kg. Neurological exam including motor, sensory, and
coordination assessments, was otherwise normal. Resting
serum creatine kinase (CK) was elevated at 1290 U/L
(normal < 400) while acylcarnitine profile, and lactate,
glucose, electrolytes, transaminases levels were normal.
Furthermore, electrocardiogram and transthoracic echo-
cardiogram were both normal.
Muscle histology and enzyme histochemistry
Based on his medical history and clinical presentation as
well as laboratory findings we suspected a mitochondrial
myopathy. After informed consent, a needle muscle bi-
opsy of the vastus lateralis muscle was performed using
a 5 mm Bergstrom needle. Standard histological and
histochemical analyses were executed on fresh-frozen
10 μm sections according to established protocols [3].
Standard histology with hematoxylin and eosin (H&E)
(Fig. 1a) and Oil Red O (Fig. 1b) stains revealed a myo-
pathic picture involving enhanced variability in fiber size,
multiple central nuclei, subsarcolemmal eosinophilic ac-
cumulation, and increased amount of lipid droplets. The
fibers showing subsarcolemmal eosinophilic accumulation
were found to be ragged-red fibers in Gomori tri-
chrome stain (data not shown). Cytochrome c oxidase
(COX) (Fig. 1c) and succinate dehydrogenase (SDH)
(Fig. 1d) enzyme histochemistry revealed 32% COX-
negative fibers and multiple ragged-blue fibers, respectively.
Biochemical assay
Respiratory chain enzyme biochemistry was performed
on muscle homogenate to assess the activities of the re-
spiratory chain enzymes, following standard procedures
[4]. This assay demonstrated a severe combined respira-
tory chain defect with significantly reduced activities of
complexes I, III, and IV (residual activities 17%, 43%,
and 32%, respectively) relative to citrate synthase (CS)
when compared to 29 healthy age-matched controls
(Table 1) [5]. In addition, CS showed a significantly in-
creased activity of 205%.
Molecular studies
To investigate the molecular basis of the combined re-
spiratory chain defect, total genomic DNA including
mtDNA was extracted from muscle as well as peripheral
blood, buccal mucosa, and urinary sediment using stand-
ard methods [6]. The entire mtDNA was polymerase
chain reaction (PCR) amplified in two fragments as pre-
viously described [7]. The fragments were then subjected
to next generation sequencing with a mean coverage of
> 1000 using updated chemistry and software described
elsewhere [8]. Sequence analysis of mtDNA isolated
from muscle identified a G-to-A transition at nucleotide
position 12,294 in the MT-TL2 gene that was present at
a mutation load of 75% (Fig. 2a). The mutation was con-
firmed by direct Sanger sequencing (primers and condi-
tions are available upon request). The mutation could
not be detected in DNA isolated from urinary epithelial
cells, buccal mucosa epithelial cells or leukocytes (NGS
analysis to a mean coverage of >10,000). To investigate
whether the mutation was maternally inherited or had
arisen sporadically, the patient’s asymptomatic mother
who requested testing was examined. After informed
consent, the mother had a needle muscle biopsy per-
formed as described for the patient, and investigated by
PCR and direct Sanger sequencing of the muscle derived
mtDNA. The mutation was not detected in the mother.
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Cycle ergometry
To measure the patient’s maximal oxygen uptake
(VO2max), we had the patient perform an incremental
cycle test to exhaustion as earlier described [9]. In order
to assess the patients resting and peak exercise-induced
serum lactate levels and lactate/pyruvate ratios (L/P), we
drew 4 blood samples from the patient in relation to the
cycle test and analyzed samples for serum concentra-
tions of lactate and pyruvate. The first sample was
drawn before the test with the patient sitting quietly at
rest. The second sample was drawn when the patient be-
came exhausted and could no longer pedal the bike. The
third and fourth samples were drawn 5 and 10 min after
the end of the test, respectively. The highest serum lac-
tate concentration and highest fraction of concomitant
serum lactate and pyruvate concentrations of the last
three blood samples were considered the peak exercise-
induced serum lactate and L/P, respectively. VO2max was
20.4 ml O2 × min
−1 × kg−1 and significantly reduced com-
pared to sex- and age-matched healthy controls (~ 40 ml
O2 ×
−1 min × kg−1 ± ~ 12, mean ± 2SD) [10]. Resting
serum lactate was 1.7 mmol × l−1, which was normal (0.7–
2.1 mmol × l−1) and peak exercise-induced serum lactate
was 9.4 mmol × l−1, which was similar to that found in 13
age-matched controls (10.4 mmol × l−1 ± 2.8, mean ± SD)
[11]. Resting L/P was 30 and peak exercise-induced L/P
was 71, which were highly elevated compared to 10
healthy individuals (< ~ 10 and < ~ 30, respectively) [12].
Discussion
Pure exercise intolerance associated with exclusive affec-
tion of skeletal muscle is a very rare phenotype of pa-
tients with mitochondrial myopathy [2]. Such patients
are often mistaken for having cardiopulmonary diseases
due to the limitations in exercise performance. Here, we
describe a patient who presented with exercise intoler-
ance and CPEO associated with a m.12,294G > A muta-
tion in the MT-TL2 gene. In accordance with the
exercise intolerance reported by the patient, VO2max was
reduced to about half of normal, indicating severely im-
paired aerobic capacity in skeletal muscle. In line with a
perturbed aerobic metabolism, both resting and peak
exercise-induced L/P were elevated threefold compared
to normal. Resting serum CK was highly elevated, which
is rare in mitochondrial myopathies [13], but a sign of
significant limitation of mitochondrial function in
Fig. 1 Muscle histology and histochemistry. a H&E stain revealing an enhanced variability in fiber size and some fibers showing internalized nuclei or
increased subsarcolemmal eosinophilic accumulation. b Oil-Red-O stain revealing increased amount of lipid droplets. c COX histochemistry
demonstrating a significant number of COX-deficient fibers. d SDH histochemistry showing multiple ragged-blue-fibers with subsarcolemmal
accumulation of abnormal mitochondria
Table 1 Activities of mitochondrial enzymes in muscle
Patient Controls mean ± SD [range] (n = 29)
Complex I/CS 0.06 0.34 ± 0.09 [0.18–0.58]
Complex II/CS 0.35 0.39 ± 0.07 [0.32–0.62]
Complex III/CS 0.51 1.20 ± 0.21 [0.75–1.71]
Complex IV/CS 1.2 3.8 ± 0.7 [2.5–5.7]
CS 634 309 ± 83 [181–468]
Enzyme activity is expressed as milliunits per milliunits citrate synthase (CS).
CS activity is expressed as milliunits per milligrams protein. Reference values
are from 29 age-matched controls and expressed as mean ± SD with ranges
in brackets
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skeletal muscle along with muscle morphology showing
myopathic changes with damaged fibers, ongoing regen-
eration, mitochondrial proliferation, intra-muscular lipid
accumulation, and abundant COX-negative fibers.
It is inherently difficult to distinguish pathogenic
mtDNA mutations in MT-T genes from neutral poly-
morphisms, because they do not produce alterations in
polypeptide sequences and at the same time the nature
of mtDNA is highly polymorphic. In fact, recent studies
have stressed that many reported mtDNA mutations af-
fecting MT-T genes are likely to be neutral, polymorphic
variants [14, 15]. Thus, it is important to assign definite
pathogenicity to reported mutations by using the revised
pathogenicity scoring system that evaluates the patho-
genicity of mtDNA mutations affecting MT-T genes
based on a list of canonical criteria [15]. In this case,
there is substantial evidence that the m.12,294G > A mu-
tation is pathogenic in regard to aforementioned scoring
system and causes exercise intolerance and CPEO in the
patient. Firstly, the biochemical assay of the respiratory
chain enzymes showed significant impairment of com-
plex I, III, and IV activities and CS activity was sig-
nificantly increased as a measure of compensatory
mitochondrial proliferation. Secondly, the mutation was
heteroplasmic and most likely sporadic as it was
present in post-mitotic tissue and undetectable in mi-
totic cells and in the mother. These two characteristics
are in fact very common features of pathogenic mtDNA
mutations [16, 17]. Thirdly, the mutation disrupts a
Watson-Crick base pair that is phylogenetically highly
conserved (Fig. 2b) in the anticodon stem of the mito-
chondrial transfer RNA (mt-tRNA) Leucine (CUN)
molecule (Fig. 2c) and thus causes a conformational
change of the molecule. Actually, a recent study found
that this exact position in the anticodon stem of the
mt-tRNA molecules is generally across all 22 mt-tRNA
molecules associated with mutations that fulfill the ca-
nonical criteria for pathogenicity [18]. Fourthly, the
mutation has been reported previously in a 45-year-old
woman with the very same phenotype as our patient
[19]. On histochemistry and biochemical assay she too
had a large amount of COX-negative fibers and a severe
combined deficiency of the respiratory chain com-
plexes. Her mutation load was 59.8% in muscle, but 0%
in blood and primary myoblasts. Additionally, single-fiber
PCR analysis demonstrated that the mutation segregated
with COX-negative fibers. Based on these findings the
researchers concluded that the mutation most likely had
Fig. 2 Molecular genetic investigation and functional consequence of the m.12,294G > A mutation. a Sanger sequencing electropherograms of
MT-TL2 from muscle (top panel) and buccal mucosa (bottom panel) encompassing the heteroplasmic m.12,294G > A mutation. The arrow in the
upper panel marks the mutation. The mutation is not identified in the bottom panel and was likewise not detected in blood and urinary sediment.
b Phylogenetic conservation of the anticodon stem and in between the anticodon loop of the mt-tRNA Leucine (CUN) sequence showing the high
preservation of the affected base-pair throughout species. c Schematic representation of the mt-tRNA Leucine (CUN) cloverleaf structure showing the
mutation in the anticodon stem and the affected G-C base-pair
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arisen sporadically. Further support for pathogenicity of
the mutation comes from the finding of a mutation af-
fecting the neighboring nucleotide namely m.12,293G >
A, which was reported to be sporadic with an occur-
rence exclusively in skeletal muscle at a mutation load
of 41% giving rise to an axial myopathy in a 69-year-old
woman [20]. Exercise capacity was not examined in
these two other cases.
Considering our patient in relation to the two other
cases it is striking that the mutations appear to be spor-
adic in origin, while at the same time only affect skeletal
muscle. This suggests that these mutations are not ma-
ternally inherited, but arise sporadically in early embryo-
genesis after the differentiation of the mesoderm into
muscle progenitor cells. This lack of transmission, and
at the same time isolated organ involvement, is rare for
mtDNA point mutations, but is often seen for mtDNA
single, large-scale deletions that is a major cause of iso-
lated CPEO and myopathy [21]. Sporadic mtDNA point
mutations affecting only skeletal muscle have been pre-
viously observed in a few cases [22–24].
After our patient was diagnosed with his mitochon-
drial myopathy he was included in a randomized,
double-blinded case-control study evaluating the safety
of the drug omaveloxolone at various doses in patients
with mitochondrial myopathies (clinicaltrials.gov). He
was advised on following a fixed exercise regimen. He
was not treated with any other drugs beside omaveloxo-
lone or any supplements. At present, he is about to be
included in another drug trial.
Conclusion
Our study, together with the two previously reported pa-
tients affected in the same anticodon stem, adds to the
evidence that the m.12,294G > A mutation is pathogenic
in human mitochondrial disease. Likely, the mutation
arose sporadically in early embryogenesis after differenti-
ation of the mesoderm into muscle progenitor cells,
leading to a pure myopathic phenotype.
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